Key result
This editorial highlights recent trials, noting the Combo stent demonstrated non-inferior 1-year target vessel failure compared with everolimus-eluting stents.
Answers are grounded in this paper and cite their sources.
This editorial highlights recent advancements in percutaneous coronary intervention, including novel stent technologies and revascularization strategies for complex lesions.
For the podcast associated with this article, please visit https://academic. oup.com/eurheartj/pages/Podcasts. Since Grüntzig’s seminal first procedure in 1977,1 percutaneous coronary intervention or PCI has made impressive progress. Most importantly, the introduction of stents has markedly improved the acute and long-term results.2–4 The first stent implantations were performed in patients with dissection and acute occlusions,5 but their long-term follow-up also showed that restenosis rates were lower in those receiving a stent. A major breakthrough was the introduction of drug-eluting stents6–9 which over time brought restenosis and stent thrombosis to an all-time low. With drug-eluting stents, delayed healing and endothelial dysfunction may occur, which favours neoatherosclerosis.10 Whether biodegradable polymers are advantageous is uncertain. In their article entitled ‘Temporal course of vascular healing and neoatherosclerosis after implantation of durable- or biodegradable-polymer drug-eluting stents’, Davide Capodanno and colleagues from the University of Catania in Italy compared in vivo vessel healing and neoatherosclerosis of current-generation biodegradable polymer or durable polymer drug-eluting stents using serial optical coherence tomography (OCT) assessments.11 Ninety patients with multivessel coronary artery disease were randomized 1:1 to biodegradable polymer everolimus-eluting stents or durable polymer zotarolimus-eluting stents. The maximum length of uncovered struts at 3 months was 10 ± 8 mm in the biodegradable polymer everolimus-eluting stents group and 11 ± 7 mm in the durable polymer zotarolimus-eluting stents group, which met non-inferiority criteria (Figure 1). At 18 months, the number of patients with neoatherosclerosis was low and similar between the two stent types. Thus, biodegradable polymer everolimus-eluting stents and durable polymer zotarolimus-eluting stents exhibit a similar healing response and a low incidence of neoatherosclerosis. These results are put into context in an Editorial by Dean J. Kereiakes from the Lindner Center for Research and Education in Cincinnati in Ohio, USA.12 Upper left panel: schematic representation of heterogeneous vessel healing and atherosclerotic changes within the neointima at follow-up in stents with a polymeric carrier. Upper right panel: whisker plot summarizing the distribution of strut coverage of BP-EES and DP-ZES at post-procedure, 3 months, and 18 months. No differences were observed between stent types at any time point. No differences were also noted in the maximal length of uncovered struts at 3 months, the 3-month co-primary endpoint of the study not shown here. Bottom panel: bar plot summarizing the proportion of patients with frames of neoatherosclerosis (left), the 18-month co-primary endpoint of the study, and components of neoatherosclerosis (right) at 18 months. No differences were observed between stent types at all time points. *Proportion of embedded struts was considered a surrogate of strut coverage at post-implant. Abbreviations: BP-EES, biodegradable polymer everolimus-eluting stent; DP-ZES, durable polymer zotarolimus-eluting stent; PCI, percutaneous coronary intervention; TCFA, thin-cap fibroatheroma. (from Guagliumi G, Shimamura K, Sirbu V, Garbo R, Boccuzzi G, Vassileva A, Valsecchi O, Fiocca L, Canova P, Colombo F, Tensol Rodriguez Pereira G, Nakamura D, Attizzani GF, Cereda A, Satogami K, De Luca L, Saia F, Capodanno D. Temporal course of vascular healing and neoatherosclerosis after implantation of durable- or biodegradable-polymer drug-eluting stents. See pages 2448–2456). Since their first use, numerous stent types have been developed with different structural characteristics, polymers, and drugs. The Combo stent, which combined sirolimus and an abluminal bioabsorbable polymer with a novel endoluminal anti-CD34+ antibody coating designed to capture endothelial progenitor cells,13 and promote optimal vascular healing, is a truly innovative product. Its performance in patients has been tested in the study entitled ‘Japan–United States of America Harmonized Assessment by Randomized Multicenter Study of OrbusNEich’s Combo StEnt (Japan-USA HARMONEE) study: primary results of the pivotal registration study of combined endothelial progenitor cell capture and drug-eluting stent in patients with ischaemic coronary disease and non-ST-elevation acute coronary syndrome’ by Mitchell Krucoff from the Duke University Medical Center in Durham, North Carolina, USA.14 A total of 572 coronary patients were randomized 1:1 to the Combo or everolimus-eluting stent. Target vessel failure occurred in 7.0% with the Combo and 4.2% with the everolimus-eluting stent. Quantitative coronary angiography late loss with Combo was equivalent to that of everolimus-eluting stents. Strut coverage assessed by OCT at 1 year was superior with Combo compared with the everolimus-eluting stent. Thus, the Combo stent demonstrated non-inferior 1-year target vessel failure and late loss compared with everolimus-eluting stents, with superior strut-based tissue. These encouraging results are critically evaluated in an Editorial by Takeshi Kimura from the Kyoto University Graduate School of Medicine in Japan.15 Preliminary studies suggest that direct stenting may reduce microvascular obstruction16–18 and improve clinical outcome. Thrombus aspiration19 may facilitate direct stenting. In their article, ‘Clinical impact of direct stenting and interaction with thrombus aspiration in patients with ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention: Thrombectomy Trialists Collaboration’, Karim D. Mahmoud and colleagues from the Erasmus MC in Rotterdam, The Netherlands assessed this issue among ST-segment elevation myocardial infarction or STEMI patients undergoing PCI of whom one-third underwent direct and two-thirds conventional stenting.20 Patients undergoing direct stenting required less contrast and had shorter fluoroscopy time. After propensity matching in 10 944 patients, no significant differences were seen between direct stenting and conventional stenting with respect to 30-day or 1-year cardiovascular death and stroke rates. Thus, clinical outcomes and myocardial reperfusion measures do not differ between direct and conventional stenting, with no interaction with thrombus aspiration. These results are further evaluated in an Editorial by Franz-Josef Neumann from the Universitäts-Herzzentrum Freiburg in Bad Krozingen, Germany.21 The clinical value of PCI for chronic total coronary occlusions is not established by randomized trials.22 In their article entitled ‘A randomized multicentre trial to compare revascularization with optimal medical therapy for the treatment of chronic total coronary occlusions’, Gerald S. Werner and the EUROCTO trial investigators compared the effects of PCI and optimal medical therapy on the health status of 396 patients with chronic total occlusion with 2:1 randomization using intention-to-treat analysis.23 At 12 months, a greater improvement of Seattle angina questionnaire subscales was noted with PCI as compared with optimal medical therapy for angina and quality of life, as was the case for physical limitation (Figure 2). Complete freedom from angina was more frequent with PCI than with optimal medical therapy. However, at 12 months, major adverse cardiac events were comparable between the two groups. Thus, in patients with stable angina and a chronic total occlusion, PCI primarily leads to an improvement of health status compared with optimal medical therapy alone. These relevant findings are put into context in an Editorial by Spencer B. King III from Saint Joseph’s Health System in Atlanta, Georgia, USA.24 Comparison of SAQ subscale changes between OMT and PCI (from Werner GS, Martin-Yuste V, Hildick-Smith D, Boudou N, Sianos G, Gelev V, Rumoroso JR, Erglis A, Christiansen EH, Escaned J, di Mario C, Hovasse T, Teruel L, Bufe A, Lauer B, Bogaerts K, Goicolea J, Spratt JC, Gershlick AH, Galassi AR, Louvard Y; for the EUROCTO trial investigators. A randomized multicentre trial to compare revascularization with optimal medical therapy for the treatment of chronic total coronary occlusions. See pages 2484–2493). Coronary artery disease has many risk factors and causes, but one that has been neglected is addressed in a review entitled ‘Fructose metabolism, cardiometabolic risk, and the epidemic of coronary artery disease’ by Peter Mirtschink and colleagues from the Universitatsklinikum Carl Gustav Carus in Dresden, Germany.25 Recently, increased attention has been given to the role of fructose as a driver of the cardiometabolic syndrome. The primary organs capable of metabolizing fructose include the liver, small intestine, and kidneys where metabolism is initiated by ketohexokinase isoform C. The authors highlight recent progress in understanding how fructose metabolism contributes to the development of major systemic pathologies that promote cardiometabolic and cardiovascular disease, and discuss how this understanding is shaping preventive actions and therapeutic approaches. The editors hope that readers of this issue of the European Heart Journal will find it of interest.
No takes yet. Share an insight, caveat, or question.
Thomas F. Lüscher (2018) conducted an editorial in Coronary artery disease. Percutaneous coronary intervention and modern stents was evaluated. This editorial highlights recent trials, noting the Combo stent demonstrated non-inferior 1-year target vessel failure compared with everolimus-eluting stents.
Synapse has enriched 10 related papers. Consider them for comparative context: